Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Flezelastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 13/20 | 0.65 |
| ▸ | HRH1 known ✓ | P35367 | 13/20 | 0.65 |
| ▸ | ADRA1B known ✓ | P35368 | 13/20 | 0.65 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 8/20 | 0.65 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.61 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.61 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.61 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.61 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.61 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.61 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.61 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.61 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.61 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.61 |
| ▸ | HTR1E known ✓ | P28566 | 1/20 | 0.61 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.61 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.61 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.61 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.59 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flezelastine SCHEMBL29687099 | 0.99 | ADRA1A (0.66) | ADRA1AHRH1ADRA1BHRH3ADRA2A | |
| Flezelastine SCHEMBL62291 | 0.99 | ADRA1A (0.66) | ADRA1AHRH1ADRA1BHRH3ADRA2A | |
| SCHEMBL10372558 | 0.90 | ADRA1A (0.79) | ADRA1AHRH1ADRA1BHRH3ADRA2A | |
| SCHEMBL10557080 | 0.90 | ADRA1A (0.64) | ADRA1AHRH1ADRA1BHRH3ADRA2A | |
| SCHEMBL10766274 | 0.85 | ADRA1A (0.65) | ADRA1AHRH1ADRA1BHRH3ADRA2A | |
| SCHEMBL2615138 | 0.84 | HRH1 (0.81) | ADRA1AHRH1ADRA1BHRH3ADRA2A | |
| SCHEMBL2615137 | 0.84 | HRH1 (0.81) | ADRA1AHRH1ADRA1BHRH3ADRA2A | |
| SCHEMBL10557572 | 0.82 | ADRA1A (0.80) | ADRA1AHRH1ADRA1BHRH3ADRA2A | |
| SCHEMBL10375081 | 0.81 | ADRA1A (0.75) | ADRA1AHRH1ADRA1BHRH3ADRA2A | |
| Hydrochloric Acid SCHEMBL2822217 | 0.80 | ADRA1A (0.76) | ADRA1AHRH1ADRA1BHRH3ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150320697-A1 | Methods For Bone Treatment By Modulating An Arachidonic Acid Metabolic or Signaling Pathway | ACCELALOX, INC. | 2015-11-12 | — | — | US | claimed |
| EP-1947942-B1 | METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | ACCELALOX INC (US) | 2015-07-29 | — | — | EP | claimed |
| US-8980851-B2 | Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway | ACCELALOX, INC. (US) | 2015-03-17 | — | — | US | claimed |
| WO-2014031586-A2 | METHODS FOR TREATING CARDIOVASCULAR DISEASES | TALLIKUT PHARMACEUTICALS, INC. (US) | 2014-02-27 | — | — | WO | claimed |
| US-20110124717-A1 | Methods for Bone Treatment by Modulating an Arachidonic Acid Metabolic or Signaling Pathway | ACCELALOX, INC. (US) | 2011-05-26 | — | — | US | claimed |
| US-7829535-B2 | for promoting osteogenesis to accelerate or enhance bone fracture healing, treat bone defects, and enhance bone formation are disclosed. The methods modulate an arachidonic acid metabolic or signaling pathway in general, and, in particular, utilize 5-lipoxygenase inhibitors. | ACCELALOX, INC. (US) | 2010-11-09 | — | — | US | claimed |
| US-20080280826-A1 | for promoting osteogenesis to accelerate or enhance bone fracture healing, treat bone defects, and enhance bone formation are disclosed. The methods modulate an arachidonic acid metabolic or signaling pathway in general, and, in particular, utilize 5-lipoxygenase inhibitors. | ACCELALOX, INC. (US) | 2008-11-13 | — | — | US | claimed |
| EP-1947942-A2 | METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | Accelalox, Inc. (US) | 2008-07-30 | — | — | EP | claimed |
| WO-2007022427-A9 | METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | ACCELALOX INC (US) | 2007-10-18 | — | — | WO | claimed |
| WO-2007022427-A2 | METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | ACCELALOX, INC. (US) | 2007-02-22 | — | — | WO | claimed |
| EP-0833622-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | SEARLE & CO (US) | 2005-08-10 | — | — | EP | claimed |
| US-20020143033-A1 | Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | G.D. SEARLE & CO. | 2002-10-03 | — | — | US | claimed |
| US-6376528-B1 | SYNERGISTIC MIXTURE | G. D. SEARLE & CO. | 2002-04-23 | — | — | US | claimed |
| EP-0888127-B1 | COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS | SEARLE & CO (US) | 2001-12-12 | — | — | EP | claimed |
| EP-0659744-B1 | Process of preparation of hexahydroazepinones and hexahydroazepinoles | ASTA MEDICA AG (DE) | 2001-02-28 | — | — | EP | claimed |
| US-6136839-A | USING A SULFONE OR SULFOAMIDE BENZENE COMPOUND | G. D. SEARLE & CO. (US) | 2000-10-24 | — | — | US | claimed |
| EP-0888127-A1 | COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1999-01-07 | — | — | EP | claimed |
| EP-0833622-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1997029776-A1 | COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-08-21 | — | — | WO | claimed |
| WO-1996041626-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143033-A1 | Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | ALOX5, ALOX15B, ALOX15 | ADRA1A 3301/4885HRH1 1682/4885ADRA1B 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.